Deltex Medical Group PLC Notice of Results (0320B)
September 18 2018 - 2:02AM
UK Regulatory
TIDMDEMG
RNS Number : 0320B
Deltex Medical Group PLC
18 September 2018
18 September 2018
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Notice of Interim Results
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), will be announcing its
Interim Results for the six months ended 30 June 2018 on Monday 24
September 2018.
Management will be hosting a presentation for analysts on the
day of results at 9:45 a.m. at the offices of Arden Partners plc,
125 Old Broad Street, London, EC2N 1AR.
Analysts who wish to attend should register their interest with
Heather Armstrong contactable at
heather.armstrong@investor-focus.co.uk or 0203 934 6630.
Deltex Medical Group plc 01243 774 837
investorinfo@Deltexmedical.com
Nigel Keen, Chairman
Andy Mears, Chief Executive
Jonathan Shaw, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 621 4120
info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 934 6630
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary oesophageal doppler
monitoring ("ODM") (TrueVue Doppler) is the only technology to
measure blood flow in the central circulation in real time.
Minimally invasive, easy to set-up and quick to focus, the
technology generates a low-frequency ultrasound signal which is
highly sensitive to changes in flow and measures such changes in
'real time'. Deltex Medical has been the only group in the enhanced
haemodynamic space to build a robust and credible evidence base
proving the clinical and economic benefits of its core technology,
TrueVue Doppler, which has been demonstrated to reduce
complications suffered by patients after surgery and save hospitals
the costs of treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which creates an
electrical field across the chest and measures the disruption to
this field when the heart pumps blood. TrueVue PressureWave uses
the peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Group goal
Haemodynamic management is now becoming widely accepted as an
important part of the anaesthesia protocol for high risk surgical
patients. Consequently, the Group's focus is on maximising value
from the opportunities presented, as enhanced haemodynamic
management is adopted into routine clinical practice around the
world. The Group aims to provide clinicians with a single platform
- a 'haemodynamic workstation' - which offers them a range of
technologies from simple to sophisticated to be deployed according
to the patient's condition as well as the skill and expertise of
the user. Doing this will enable the Group to partner healthcare
providers to support modern haemodynamic management across the
whole hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA - and through distribution arrangements in
approximately 40 other countries.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORQDLFFVKFXBBZ
(END) Dow Jones Newswires
September 18, 2018 02:02 ET (06:02 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024